バーチャル腫瘍学の世界市場

バーチャル腫瘍学の世界市場は2030年までに102億米ドルに達する見込み

2024年に39億米ドルと推定されるバーチャル腫瘍学の世界市場は、2024年から2030年にかけてCAGR 17.4％で成長し、2030年には102億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるソフトウェアは、CAGR19.2％を記録し、分析期間終了時には63億米ドルに達すると予測されます。サービス分野の成長率は、分析期間中CAGR 14.4%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR23.2％で成長予測

米国のバーチャル腫瘍学市場は2024年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに23億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは23.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.7%と15.8%と予測されています。欧州では、ドイツがCAGR約13.9%で成長すると予測されています。

世界の「バーチャル腫瘍学」市場- 主要動向と促進要因のまとめ

バーチャル腫瘍学はデジタル時代のがん医療をどう変革するか？

従来のがん治療をデジタル化したバーチャル腫瘍学は、患者が地理的・移動的制約を受けることなく、診断、治療計画、セカンドオピニオン、フォローアップ治療にアクセスする方法を再定義しています。その中核となるバーチャル腫瘍学は、遠隔医療プラットフォーム、AIを活用した診断、遠隔モニタリングツールを活用し、個別化されたがん治療を効率的かつ公平に提供します。患者は国境を越えてがん専門医に相談し、安全なポータルを介して診断スキャンを共有し、長距離を移動することなく治療レジメンについて専門家の意見を聞くことができます。これは、腫瘍学の専門医や先進的ながんセンターが利用できないことが多い、地方や十分な医療を受けられない人々にとって、特に価値のあることです。バーチャル腫瘍委員会や集学的なe-コンサルを通じて、各施設の臨床医がリアルタイムで協力し、的確な治療戦略を立てることができます。COVID-19の大流行は、遠隔腫瘍学プラットフォームの採用を加速させ、病院やがんセンターを、進行中のがん治療をバーチャルで管理するための安全でHIPAAに準拠したシステムの開発に駆り立てた。現在、物理的な業務が再開されても、多くの医療提供者は、特にサバイバーシップケア、遺伝カウンセリング、定期的な評価のために、対面での処置とバーチャルな診察を融合させたハイブリッドケアモデルを維持しています。その結果、より合理的で、継続的で、患者中心のがん治療モデルが実現し、遅れが減少し、アクセスが向上しています。

AIはバーチャル腫瘍学サービスの基幹になりつつあるか？

人工知能は、診断精度の向上、治療効果の予測、日常的な臨床ワークフローの自動化により、バーチャル腫瘍学の重要な実現要素として台頭してきています。AIを搭載した画像処理プラットフォームは、放射線科医がCT、MRI、PETスキャンで腫瘍をより正確かつ迅速に検出する方法を変革しています。これらのシステムは膨大なデータセットを解析し、人間の目には見えないパターンを発見することができるため、肺がん、乳がん、前立腺がんなどの早期診断や病期分類が可能になります。病理学では、AIアルゴリズムが生検スライドのデジタル解析を支援し、病理医が遠隔操作で一貫して腫瘍の種類を分類するのに役立っています。自然言語処理（NLP）ツールは、腫瘍学の報告書や患者のメモから実用的な洞察を抽出し、腫瘍医の意思決定支援システムに反映させるために使用されています。AIはまた、進行リスク、副作用、標的治療の有効性を推定する予測モデルにも威力を発揮しています。これらのツールがバーチャルケアプラットフォームに統合されれば、腫瘍医は主観的な評価だけでなく、高度な分析に基づいた質の高いケアを遠隔地から提供できるようになります。さらに、腫瘍学に特化したAIチャットボットやバーチャルケアアシスタントは現在、服薬アドヒアランス、症状追跡、治療副作用管理で患者をサポートしています。

患者中心のツールはどのようにバーチャル腫瘍学のリーチを広げているのか？

デジタル治療薬や患者向けオンコロジーツールの台頭により、がん患者がバーチャル腫瘍学のサービスに参加し、恩恵を受ける方法が大幅に改善されています。オンコロジーケアのためにデザインされたモバイルアプリは現在、服薬リマインダー、痛みや症状のダイアリー、食事指導、ヘルスケアチームとの安全なメッセージングなどの機能を提供しています。これらのツールは、化学療法や免疫療法を受けている患者にとって特に重要であり、受診と受診の間の症状管理が生存期間や生活の質に影響を与える可能性があります。ウェアラブル・バイオセンサーや接続された医療機器により、臨床医は心拍数、体温、酸素飽和度などのバイタルを遠隔監視することができます。バーチャルリアリティ（VR）や拡張現実（AR）アプリケーションは、治療サイクル中の苦痛の緩和、ストレスの緩和、患者教育のための補助装置として台頭してきています。さらに、オンラインのピアサポートグループ、バーチャルカウンセリング、緩和ケアのためのデジタルプラットフォームは、がん治療で見過ごされがちな心理社会的サポートを患者と介護者の両方に提供しています。バーチャル腫瘍学のパーソナライゼーションは、分子プロファイリングデータをバーチャル治療の議論に統合し、各患者の腫瘍生物学に合わせたより的を絞った効率的な治療計画を可能にするゲノミクス・プラットフォームによってさらにサポートされています。

世界のバーチャル腫瘍学普及の原動力は？

バーチャル腫瘍学市場の成長は、腫瘍学ワークフローの進化、患者の期待、ヘルスケアのデジタル化に根ざしたいくつかの要因によってもたらされています。主な要因は、世界のがん罹患率の増加であり、従来のがん医療インフラを圧倒し、拡張性のあるデジタル代替医療への差し迫ったニーズを生み出しています。放射線画像からゲノム配列に至るまで、腫瘍学データの急速なデジタル化により、遠隔解析やクラウドベースの共同作業が可能になり、専門医が世界のどこからでも専門的な意見を提供しやすくなっています。ヘルスケアに対する消費者意識の高まりも市場力学に影響を与えており、バーチャルな診察を通じてセカンドオピニオンや利便性を求める患者が増加しています。これと並行して、医療システムや保険会社はバリューベースケアモデルの一環としてバーチャル腫瘍学プラットフォームに投資しており、入院の削減、患者の転帰の改善、がん治療費全体の削減を目指しています。EHR、PACS（画像保存通信システム）、遠隔病理学ソリューションの統合により、がんセンターはワークフローの一部をバーチャル環境に移行することがシームレスになっています。さらに、米国、カナダ、ドイツ、インドなどの主要市場では、診療報酬の平準化政策や規制当局の支援により、医療提供者にとっても患者にとっても、バーチャル腫瘍学は経済的に実現可能なものとなっています。個別化医療と免疫腫瘍学が拡大し続ける中、複雑ながん治療には、より協力的で、遠隔地にあり、インテリジェントなシステムが必要とされます。

セグメント

コンポーネント（ソフトウェア、サービス、ハードウェア）、がんの種類（肺がん、乳がん、大腸がん、前立腺がん、肝臓がん、膀胱がん、その他のがんの種類）、用途（精密医療、患者ケア管理、研究開発、臨床試験、診断・治療意思決定、データ管理、その他の用途）、エンドユーザー（病院・画像診断センター、学術機関・研究センター、製薬・バイオテクノロジー企業、契約研究機関、その他のエンドユーザー）

調査対象企業の例（注目の48社）

• Accuray Incorporated
• Amwell（American Well）
• Caris Life Sciences
• Cerner Corporation
• Color Health
• CureMatch, Inc.
• Elekta AB
• Epic Systems Corporation
• Flatiron Health
• Jasper Health
• McKesson Corporation
• OncoHealth
• OncoLens
• OneOncology
• Optum, Inc.
• Philips Healthcare
• Reimagine Care
• Siemens Healthineers
• SimBioSys
• Varian Medical Systems, Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Virtual Oncology Market to Reach US$10.2 Billion by 2030

The global market for Virtual Oncology estimated at US$3.9 Billion in the year 2024, is expected to reach US$10.2 Billion by 2030, growing at a CAGR of 17.4% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Service segment is estimated at 14.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 23.2% CAGR

The Virtual Oncology market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 23.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.7% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.9% CAGR.

Global "Virtual Oncology" Market - Key Trends & Drivers Summarized

How Is Virtual Oncology Transforming Cancer Care in the Digital Era?

Virtual oncology, the digital extension of traditional cancer care, is redefining how patients access diagnostics, treatment planning, second opinions, and follow-up care without geographic or mobility constraints. At its core, virtual oncology leverages telemedicine platforms, AI-enhanced diagnostics, and remote monitoring tools to deliver personalized cancer care efficiently and equitably. Patients can now consult oncologists across borders, share diagnostic scans via secure portals, and receive expert input on treatment regimens without traveling long distances. This is particularly valuable for rural and underserved populations where oncology specialists and advanced cancer centers are often unavailable. Through virtual tumor boards and multidisciplinary e-consultations, clinicians across institutions collaborate in real-time to develop precise treatment strategies. The COVID-19 pandemic accelerated the adoption of tele-oncology platforms, pushing hospitals and cancer centers to develop secure, HIPAA-compliant systems to manage ongoing cancer therapies virtually. Now, even as physical operations resume, many providers are retaining hybrid care models that blend in-person procedures with virtual consultations, especially for survivorship care, genetic counseling, and routine assessments. The result is a more streamlined, continuous, and patient-centric cancer care model that reduces delays and improves access.

Is AI Becoming the Backbone of Virtual Oncology Services?

Artificial intelligence is emerging as a vital enabler of virtual oncology by enhancing diagnostic accuracy, predicting treatment response, and automating routine clinical workflows. AI-powered imaging platforms are transforming how radiologists detect tumors in CT, MRI, and PET scans with greater precision and speed. These systems can analyze massive datasets to uncover patterns that are often invisible to the human eye, enabling early diagnosis and staging of cancers like lung, breast, and prostate. In pathology, AI algorithms are assisting in the digital analysis of biopsy slides, helping pathologists classify tumor types remotely and consistently. Natural language processing (NLP) tools are being used to extract actionable insights from oncology reports and patient notes, feeding into decision-support systems for oncologists. AI is also powering predictive models that estimate progression risks, adverse drug reactions, and the likely efficacy of targeted therapies - allowing oncologists to tailor treatments in advance. These tools, when integrated into virtual care platforms, enable oncologists to deliver high-quality care from a distance, informed by advanced analytics rather than just subjective assessments. Furthermore, oncology-focused AI chatbots and virtual care assistants are now supporting patients in medication adherence, symptom tracking, and treatment side effect management - all in real-time and without the need for clinic visits.

How Are Patient-Centered Tools Enhancing the Reach of Virtual Oncology?

The rise of digital therapeutics and patient-facing oncology tools is significantly improving how cancer patients engage with and benefit from virtual oncology services. Mobile apps designed for oncology care now offer features like medication reminders, pain and symptom diaries, dietary guidance, and secure messaging with healthcare teams. These tools are particularly important for patients undergoing chemotherapy or immunotherapy, where symptom management between visits can impact survival and quality of life. Wearable biosensors and connected medical devices allow clinicians to remotely monitor vitals such as heart rate, temperature, and oxygen saturation - metrics that can indicate adverse drug reactions or infections in immunocompromised patients. Virtual reality (VR) and augmented reality (AR) applications are emerging as adjuncts for pain distraction, stress relief, and patient education during therapy cycles. Moreover, online peer support groups, virtual counseling, and digital platforms for palliative care are offering psychosocial support to both patients and caregivers, which is an often-overlooked aspect of cancer treatment. The personalization of virtual oncology is further supported by genomics platforms that integrate molecular profiling data into virtual treatment discussions, allowing for more targeted and efficient care plans tailored to each patient’s tumor biology.

What’s Driving the Surge in Global Virtual Oncology Adoption?

The growth in the virtual oncology market is driven by several factors rooted in the evolution of oncology workflows, patient expectations, and healthcare digitization. A key factor is the global increase in cancer incidence, which has overwhelmed traditional cancer care infrastructures, creating a pressing need for scalable digital alternatives. The rapid digitization of oncology data - from radiological images to genomic sequences - has enabled remote analysis and cloud-based collaboration, making it easier for specialists to provide expert opinions from anywhere in the world. Rising healthcare consumerism has also influenced market dynamics, with patients increasingly seeking second opinions and convenience through virtual consultations. In parallel, health systems and insurers are investing in virtual oncology platforms as part of value-based care models, aiming to reduce hospitalizations, improve patient outcomes, and lower overall cancer treatment costs. The integration of EHRs, PACS (Picture Archiving and Communication Systems), and telepathology solutions is making it seamless for cancer centers to transition parts of their workflow into virtual environments. Additionally, reimbursement parity policies and regulatory support in major markets like the U.S., Canada, Germany, and India have made virtual oncology financially viable for providers and patients alike. As personalized medicine and immuno-oncology continue to expand, the complexity of cancer care will require more collaborative, remote, and intelligent systems - all of which are at the heart of the virtual oncology ecosystem.

SCOPE OF STUDY:

The report analyzes the Virtual Oncology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Software, Service, Hardware); Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Other Cancer Types); Application (Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management, Other Applications); End-User (Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Accuray Incorporated
• Amwell (American Well)
• Caris Life Sciences
• Cerner Corporation
• Color Health
• CureMatch, Inc.
• Elekta AB
• Epic Systems Corporation
• Flatiron Health
• Jasper Health
• McKesson Corporation
• OncoHealth
• OncoLens
• OneOncology
• Optum, Inc.
• Philips Healthcare
• Reimagine Care
• Siemens Healthineers
• SimBioSys
• Varian Medical Systems, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Virtual Oncology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Remote Cancer Consultations and Follow-Ups Spur Growth of Virtual Oncology Services
  • Increasing Cancer Prevalence Worldwide Expands Addressable Market for Tele-Oncology Solutions
  • Integration of Genomic and Imaging Data in Virtual Platforms Strengthens Case for Precision Oncology
  • Pandemic-Induced Shift to Virtual Care Accelerates Demand for Digital Oncology Platforms
  • Advancements in AI-Based Tumor Diagnostics Drive Adoption of Virtual Oncology Tools
  • Growing Patient Preference for Home-Based Care Throws the Spotlight on Virtual Oncology Models
  • Shortage of Oncologists in Rural Areas Propels Growth of Remote Oncology Services
  • Expansion of Digital Clinical Trials Creates New Avenues for Virtual Oncology Solutions
  • Enhanced Reimbursement Frameworks Strengthen Market Viability of Tele-Oncology
  • Virtual Tumor Boards and Multidisciplinary Collaboration Accelerate Treatment Decision Making
  • Integration with Remote Monitoring Devices Sustains Growth in Post-Treatment Virtual Care
  • Increased Focus on Patient-Centered Care Models Generates Opportunities for Virtual Oncology Apps
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Virtual Oncology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Virtual Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Virtual Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hardware by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Hardware by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Precision Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Precision Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Patient Care Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World 6-Year Perspective for Patient Care Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World 6-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 30: World Recent Past, Current & Future Analysis for Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 31: World 6-Year Perspective for Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Diagnosis & Treatment Decision Making by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World 6-Year Perspective for Diagnosis & Treatment Decision Making by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Data Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 35: World 6-Year Perspective for Data Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 36: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 37: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Imaging Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World 6-Year Perspective for Hospitals & Diagnostic Imaging Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 40: World Recent Past, Current & Future Analysis for Academic Institutions & Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 41: World 6-Year Perspective for Academic Institutions & Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 42: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 43: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World 6-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
  • TABLE 46: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 47: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 48: USA Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: USA 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 52: USA Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: USA 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 54: USA Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: USA 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 58: Canada Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Canada 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 60: Canada Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Canada 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• JAPAN
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 64: Japan Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Japan 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 66: Japan Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Japan 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 70: Japan Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Japan 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• CHINA
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 72: China Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: China 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 76: China Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: China 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 78: China Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: China 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• EUROPE
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Virtual Oncology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe 6-Year Perspective for Virtual Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 82: Europe Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Europe 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 84: Europe Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Europe 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 88: Europe Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Europe 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• FRANCE
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 90: France Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: France 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 94: France Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: France 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 96: France Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: France 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• GERMANY
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 100: Germany Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 101: Germany 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 102: Germany Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 103: Germany 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• ITALY
  • TABLE 106: Italy Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 107: Italy 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 108: Italy Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 109: Italy 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 112: Italy Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 113: Italy 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• UNITED KINGDOM
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 114: UK Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 115: UK 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 118: UK Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 119: UK 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 120: UK Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 121: UK 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 124: Spain Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 125: Spain 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 126: Spain Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 127: Spain 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• RUSSIA
  • TABLE 130: Russia Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 131: Russia 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 132: Russia Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 133: Russia 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 136: Russia Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 137: Russia 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 138: Rest of Europe Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 139: Rest of Europe 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 142: Rest of Europe Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 143: Rest of Europe 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 144: Rest of Europe Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 145: Rest of Europe 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• ASIA-PACIFIC
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific 6-Year Perspective for Virtual Oncology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
  • TABLE 148: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 149: Asia-Pacific 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 150: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 151: Asia-Pacific 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 154: Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 155: Asia-Pacific 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• AUSTRALIA
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 156: Australia Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 157: Australia 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 160: Australia Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 161: Australia 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 162: Australia Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 163: Australia 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• INDIA
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 166: India Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 167: India 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 168: India Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 169: India 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• SOUTH KOREA
  • TABLE 172: South Korea Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 173: South Korea 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 174: South Korea Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 175: South Korea 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 178: South Korea Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 179: South Korea 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 180: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 184: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 185: Rest of Asia-Pacific 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 186: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• LATIN AMERICA
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America 6-Year Perspective for Virtual Oncology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
  • TABLE 190: Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 191: Latin America 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 192: Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 193: Latin America 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 196: Latin America Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 197: Latin America 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• ARGENTINA
  • TABLE 198: Argentina Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 199: Argentina 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 202: Argentina Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 203: Argentina 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 204: Argentina Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 205: Argentina 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 208: Brazil Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 209: Brazil 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 210: Brazil Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 211: Brazil 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• MEXICO
  • TABLE 214: Mexico Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 215: Mexico 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 216: Mexico Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 217: Mexico 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 220: Mexico Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 221: Mexico 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 222: Rest of Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 223: Rest of Latin America 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 226: Rest of Latin America Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 227: Rest of Latin America 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 228: Rest of Latin America Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 229: Rest of Latin America 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• MIDDLE EAST
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 230: Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 231: Middle East 6-Year Perspective for Virtual Oncology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
  • TABLE 232: Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 233: Middle East 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 234: Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 235: Middle East 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 238: Middle East Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 239: Middle East 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• IRAN
  • TABLE 240: Iran Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 241: Iran 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 242: Iran Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Iran 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 244: Iran Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 245: Iran 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 246: Iran Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 247: Iran 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• ISRAEL
  • TABLE 248: Israel Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Israel 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 250: Israel Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 251: Israel 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 252: Israel Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 253: Israel 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• SAUDI ARABIA
  • TABLE 256: Saudi Arabia Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 257: Saudi Arabia 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 258: Saudi Arabia Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 259: Saudi Arabia 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 260: Saudi Arabia Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Saudi Arabia 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 262: Saudi Arabia Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 263: Saudi Arabia 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 264: UAE Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 265: UAE 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 266: UAE Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: UAE 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 268: UAE Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 269: UAE 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 270: UAE Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 271: UAE 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 272: Rest of Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Rest of Middle East 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 274: Rest of Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 275: Rest of Middle East 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 276: Rest of Middle East Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 277: Rest of Middle East 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 278: Rest of Middle East Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Rest of Middle East 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030
• AFRICA
  • Virtual Oncology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 280: Africa Recent Past, Current & Future Analysis for Virtual Oncology by Component - Software, Service and Hardware - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 281: Africa 6-Year Perspective for Virtual Oncology by Component - Percentage Breakdown of Value Sales for Software, Service and Hardware for the Years 2025 & 2030
  • TABLE 282: Africa Recent Past, Current & Future Analysis for Virtual Oncology by Cancer Type - Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 283: Africa 6-Year Perspective for Virtual Oncology by Cancer Type - Percentage Breakdown of Value Sales for Other Cancer Types, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Bladder Cancer for the Years 2025 & 2030
  • TABLE 284: Africa Recent Past, Current & Future Analysis for Virtual Oncology by Application - Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Africa 6-Year Perspective for Virtual Oncology by Application - Percentage Breakdown of Value Sales for Precision Medicine, Patient Care Management, Research & Development, Clinical Trials, Diagnosis & Treatment Decision Making, Data Management and Other Applications for the Years 2025 & 2030
  • TABLE 286: Africa Recent Past, Current & Future Analysis for Virtual Oncology by End-user - Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 287: Africa 6-Year Perspective for Virtual Oncology by End-user - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Imaging Centers, Academic Institutions & Research Centers, Pharma & Biotech Companies, Contract Research Organizations and Other End-Users for the Years 2025 & 2030

IV. COMPETITION